AMR

Meguro-ku, Japan
Meguro-ku, Japan

Time filter

Source Type

News Article | May 15, 2017
Site: www.marketwired.com

LENEXA, KS--(Marketwired - May 15, 2017) - Digital Ally, Inc. ( : DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, today announced its operating results for the first quarter of 2017. An investor conference call is scheduled for 11:15 a.m. EDT on May 15, 2017 (see details below). "We are excited to report that first quarter revenues were up 19% from prior-year levels and 52% on a sequential basis," stated Stanton E. Ross, Chief Executive Officer of Digital Ally Inc. "We shipped more mirrors in first quarter 2017 than any quarter since 2010 and our service revenues were up 71% in the three months ended March 31, 2017 compared to year-earlier levels. Our strategy of expanding our recurring service-based revenue to help stabilize and grow our revenues on a quarterly basis is apparent in our first quarter 2017 results." "We are pursuing several new market channels that do not involve our traditional law enforcement and private security customers and utilize our core technology of mobile audio/video recording equipment together with our cloud storage and archiving services. These new market channels do not effectively utilize the power of audio/video recordings, which could represent very large untapped addressable markets for our products and services. If successful, we believe that these new market channels could yield increased recurring service revenues for us in 2017 and beyond," Mr. Ross continued. "We are promoting a new revenue model that bundles our product offerings, including the long-term lease of our body-worn and/or in-car audio/video hardware, together with a monthly subscription for our cloud storage, search and archiving services for the underlying audio and video material. We believe this revenue service model may appeal to our customers, in particular our commercial and other non-law enforcement customers because it reduces the capital outlay up front and eliminates repairs and maintenance in exchange for level monthly payments for the utilization of the equipment, data storage and management services." "We recently announced the launch of the DVM-800 HD in-car video system, which we believe will be disruptive in the market and will lead to an expansion of our overall market share in the law enforcement channel. The DVM-800 HD system provides full 1080P high definition video at a cost-effective price point, which we believe is a competitive market advantage for us." "Our international revenues decreased to $29,806 in first quarter 2017 compared to $313,729 during 2016. Our first quarter 2017 international revenues were disappointing after several positive quarters; however, the international sales cycle generally takes longer than domestic business and we have a number of bids outstanding to international customers." "We had approximately $6.8 million in net working capital available at March 31, 2017, including $3.4 million of accounts receivable and $9.7 million of inventory. We raised $4.0 million through the issuance of 8% Secured Convertible Debentures in December 2016. These mature in March 2018 unless converted by their holders at $5.00 per share before such date. The Debentures represent a current liability as of March 31, 2017. Our goal is to reduce inventory levels during 2017 to provide additional working capital and improve our operating results to generate the funds to retire the Debentures. We may also pursue the raise of additional capital if required," concluded Ross. For the three months ended March 31, 2017, our total revenue increased by 19% to approximately $5.2 million, compared with revenue of approximately $4.4 million for the three months March 31, 2016. This increase was primarily due to the large commercial order received in the first quarter 2017 from AMR for DVM-250 event recorders with FleetVU and asset tracking service. The AMR contract was for 1,550 DVM-250 systems as well as FleetVU manager cloud storage and system implementation, most of which were delivered in first quarter 2017 and had a positive impact on revenues. International revenue decreased to $29,806 during first quarter 2017, versus $313,729 during first quarter 2016. Gross profit increased 23% to $2,276,849 for the three months ended March 31, 2017, versus $1,853,619 in 2016. Our gross margin increase is commensurate with the 19% increase in revenues for the three months ended March 31, 2017 and the cost of sales as a percentage of revenues decreasing to 56% from 58% for the three months ended March 31, 2016. We expect that gross margins will continue to improve in 2017 because we believe we have corrected the quality control and other warranty related issues affecting our FirstVU HD product during recent quarters. Our goal is to improve our margins to 60% over the longer term based on the expected margins of our newer products, in particular the DVM-800, DVM-800 HD and FirstVU HD, as they continue to gain traction in the marketplace and we increase our commercial market penetration in 2017. In addition, as revenues from these products increase, we will seek to further improve our margins from them through economies of scale and more efficiently utilizing fixed manufacturing overhead components. We plan to continue our initiative on more efficient management of our supply chain through outsourcing production, quantity purchases and more effective purchasing practices. Selling, General and Administrative ("SG&A") expenses decreased approximately 3% to $4,079,062 in the three months ended March 31, 2017, versus $4,191,514 a year earlier. We reported an operating loss of ($1,802,213) for the three months ended March 31, 2017, compared with an operating loss of ($2,337,895) in the previous year. Interest income decreased to $5,061 in first quarter 2017, from $8,992 in 2016. Non-cash charges totaled ($155,252) in first quarter 2017 compared with non-cash income of $16,533 in the year-earlier quarter. Such non-cash income (charges) reflect changes in the fair value of the secured convertible debentures and warrant derivatives. We elected to record the $4.0 million secured convertible debentures issued in December 2016 on their fair value basis and recorded a loss of $155,857 due to the change in their fair value as of March 31, 2017. Warrants to purchase 12,200 common shares remain unexercised at March 31, 2017 and 2016, which are treated as derivative liabilities, and we recorded income of $605 due to the change in their fair value as of March 31, 2017. Interest expense totaled $80,551 in the three months ended March 31, 2017, compared to $755 in the three months ended March 31, 2016. We issued an aggregate of $4.0 million principal amount of secured convertible debentures on December 30, 2016 which bore interest at the rate of 8% per annum and remained outstanding at March 31, 2017. No similar interest bearing debt was outstanding during the 2016 period. We reported a net loss of ($2,032,955), or ($0.36) per share, in the first quarter of 2017, compared with a prior-year net loss of ($2,313,125), or ($0.44) per share. No income tax provision or benefit was recorded in the first quarter of either 2017 or 2016. We expect to continue to maintain a full valuation allowance on our deferred tax assets, including net operating loss carry forwards, until we determine that we can sustain a level of profitability that demonstrates our ability to realize such assets. During first quarter 2017, we increased our valuation reserve on deferred tax assets by approximately $715,000. As of March 31, 2017, we had approximately $41.7 million of net operating loss carryforwards and $2.0 million of research and development tax credit carryforwards available to offset future net taxable income. On a non-GAAP basis, we reported an adjusted net loss (before depreciation, amortization, net interest expense, change in derivative liabilities, change in the fair value of secured convertible notes, secured convertible debentures issuance expense, and stock-based compensation), of ($1,256,544), or ($0.22) per share, for the quarter ended March 31, 2017, versus a non-GAAP adjusted net loss of ($1,760,047), or ($0.34) per diluted share, in the first quarter of 2016. (Non-GAAP adjusted net loss is described in greater detail in a table at the end of this press release). Digital Ally, Inc. has provided financial information in this release that has not been prepared in accordance with GAAP. This information includes non-GAAP adjusted EBITDA loss. Digital Ally uses such non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to GAAP measures, in evaluating Digital Ally's ongoing operational performance. Digital Ally believes that the use of these non-GAAP financial measures provides an additional tool for investors to evaluate ongoing operating results and trends and in comparing its financial measures with other companies in Digital Ally's industry, many of which present similar non-GAAP financial measures to investors. As noted, the non-GAAP financial measures discussed above exclude certain non-cash and/or non-recurring expenses/income including: (1) depreciation and amortization expense, (2) net interest expense, (3) share-based compensation expense, (4) changes in fair value of secured convertible notes payable, (5) secured convertible debentures issuance expense, (6) and changes in warrant derivative valuations. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure as detailed above. As previously mentioned, a reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release. The Company will host an investor conference call at 11:15 a.m. Eastern Daylight Time (EDT) on Monday, May 15, 2017, to discuss its operating results for the first quarter 2017, along with other topics of interest. Shareholders and other interested parties may participate in the conference call by dialing 844-761-0863 and entering conference ID# 18527706 a few minutes before 11:15 a.m. Eastern Daylight Time on Monday, May 15, 2017. A replay of the conference call will be available two hours after its completion, from May 15, 2017 until 11:59 p.m. on August 15, 2017 by dialing 855-859-2056 and entering the conference ID# 18527706. Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Company's primary focus is digital video imaging and storage. The Company is headquartered in Lenexa, Kansas, and its shares are traded on The Nasdaq Capital Market under the symbol "DGLY." For additional news and information please visit www.digitalallyinc.com or follow us on Twitter @digitalallyinc and Facebook www.facebook.com/DigitalAllyInc This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: whether the Company will be able to improve its revenue and operating results, including to the extent necessary to retire the Secured Convertible Debentures; whether it will be able to raise capital, and do so on terms favorable to the Company, to retire such Debentures, if required; whether it will be able to achieve improved production and other efficiencies to restore its gross and operating margins to targeted levels in 2017 and beyond; whether the Company will be able to continue to expand into non-law enforcement markets; whether the Company will be successful in increasing its recurring revenue; whether the Company has resolved its product quality issues; whether there will be commercial markets, domestically and internationally, for one or more of the Company's newer products, and the degree to which the interest shown in its newer products, including the FirstVU HD, DVM-800 HD, VuLink, VuVault.net and FleetVU, will continue to translate into sales in future periods; whether the Company's "auto-activation" technology is becoming a standard feature for agencies utilizing body-worn cameras; whether the Company will achieve positive outcomes in its litigation with various parties, including Axon Enterprise, Inc. (formerly Taser International), Utility Associates and WatchGuard; whether the USPTO rulings will curtail, eliminate or otherwise have an effect on the actions of Taser, Utility Associates and WatchGuard respecting the Company, its products and customers; whether the outstanding common stock purchase warrants will be exercised for cash; the Company's ability to deliver its newer product offerings, including the FirstVU HD and DVM-800 HD, as scheduled, obtain the required components and products on a timely basis, and have them perform as planned; its ability to maintain or expand its share of the markets in which it competes, including those outside the law enforcement industry; whether the Company will be able to adapt its technology to new and different uses, including being able to introduce new products; whether and the extent to which the new patents allowed by the USPTO will give the Company effective, enforceable protection of the intellectual property contained in its products in the marketplace; competition from larger, more established companies with far greater economic and human resources; its ability to attract and retain customers and quality employees; the effect of changing economic conditions; and changes in government regulations, tax rates and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether because of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in its annual report on Form 10-K for the year ended December 31, 2016 and quarterly report on Form 10-Q for the three months ended March 31, 2017, as filed with the Securities and Exchange Commission.


News Article | May 15, 2017
Site: www.prweb.com

Today, the founders of British Medical Auctions and Centurion Service Group announced an exclusive partnership that offers industry-leading strengths of each company to a form a new Dubai-based auction house coined Arabian Medical Remarketing (AMR). Founder and CEO of Centurion Service Group, Erik Tivin, has over 20 years’ experience in the U.S. medical industry. Founder and CEO of British Medical Auctions, Markus Grad, also holds over 20 years’ experience in the U.K. medical industry. Together, the two medical industry leaders, along with two other partners have come together to offer the Gulf region a solution for surplus medical equipment. Both leaders bring with them unmatchable expertise in used medical equipment live auctions, hospital liquidations and appraisals. “I have been traveling to the Gulf region for almost a decade, with the boom in health care throughout the entire region, we thought the timing was right to bring our collective sales models together to help the world class medical facilities deal with their surplus equipment needs,” said Tivin, AMR founder and CEO of Centurion Service Group. British Medical Auctions and Centurion Service Group’s shared vision for this partnership is a global effort to transform the process of selling and buying used medical equipment. Specifically, Arabian Medical Remarketing is dedicated to provide easy-to-access and cost-effective medical equipment purchasing solutions for buyers worldwide. “Our collaborative approach to the Gulf region ensures that we bring an unrivaled wealth of experience to the market and will help to facilitate a strong revenue return back to the health care industry,” AMR founder and CEO of British Medical Auctions, Grad said. “Our investment into the region shows our intent to provide a global reach for all our clients both buyers and suppliers.” Arabian Medical Remarketing is proud to be fully committed to the management of equipment from health care environments, offering a wide-range of services including independent valuations, hospital clearance, asset management, specialized collections, and live auctions. All equipment is securely stored in a AMR’s warehouse. Inspection of equipment is available prior to auctions with available staff to assist with all inquiries. Arabian Medical Remarketing is pleased to announce the kickoff of the company’s first live medical equipment auction that will take place on Wednesday, May 24, 2017 beginning at 9 a.m. BST (12 p.m. GST) via online and on-site bidding. The live auction will be held in the U.K., and the equipment is located at the Dubai warehouse. For more information about the upcoming live auction, please visit http://www.arabianmedicalremarketing.com/auctions. About Arabian Medical Remarketing: Arabian Medical Remarketing (AMR) is Dubai’s most dynamic and fastest-growing medical auction house, formed by a team of entrepreneurial professionals with over 40 years’ experience of both the medical equipment and the online and offline auction industry. They specialize in surplus, obsolete, end-of-line and decommissioned medical equipment from all health care environments. For more information about Arabian Medical Remarketing, please visit http://www.arabianmedicalremarketing.com.


News Article | April 18, 2017
Site: www.prweb.com

For a historic seventh consecutive year, Benchmark Research along with PMG Research Associates and Miami Research Associates, co-members in the VaxCorps vaccine consortium, were named one of the top two Clinical Research Sites or Network. Benchmark Research has been a top finalist since the inception of this category; winning the award four times previously, and first runner up the other three years. The only awards ceremony dedicated to the vaccine industry, the annual Vaccine Industry Excellence (ViE) Awards honor individuals, organizations and initiatives which have made significant contributions to the industry over the past 12 months. “We congratulate Brenda Atchison and AMR for their well-deserved win this year, and thank our partners in VaxCorps, PMG and QPS/MRA for working with Benchmark to become the unparalleled vaccine network in the world. We are also deeply grateful to have been in the top two sites/networks for seven consecutive years, and are proud that no other company has achieved these accolades in any other category. Finally, and most importantly, we are blessed by all the Benchmark Family employees who ultimately are responsible for this prestigious award," said Mark Lacy, CEO of Benchmark Research. Benchmark Research is a fully integrated network of multi-therapeutic research sites, spanning three states. With the innovative opening of three Urgent & Family Care Centers this past year, Benchmark Research is enhancing the company patient database, taking on a broader spectrum of indications and is bringing added value to patients and clients. Started in 1997, Benchmark Research continues to lead in the quest to provide excellence in the clinical research industry.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Smart Gas Market - Global Forecast to 2022" report to their offering. The smart gas market size is expected to grow from USD 11.25 billion in 2017 to USD 21.75 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 14.1% during the period of 2017-2022. The major drivers for upsurge in demand for the smart gas market include the growing demand for customer-centric approach and increasing global energy demand leading to adoption of sophisticated technologies and integrated wireless communication features in smart gas solutions reducing field visits. The limiting factors hindering the growth of the smart gas market include the lack of strong business case for the deployment of smart gas meters limiting the investment and the high Capital Expenditure (CAPEX) on the smart gas infrastructure. Meter data analytics solution unlocks smart meter data from both Automatic Meter Reading (AMR) and Advanced Metering Infrastructure (AMI) sources, turning them into actionable information for gas utilities. It enables the company staff to track performance and analyze trends using the information from the core gas utility applications. It helps improve customer service quality and cut costs by using Interactive Voice Response (IVR) systems, steering customers to self-service websites and varying billing cycles, so that call volumes are relatively leveled l throughout the month. It also reduces gas loss, resulting from pipe leaks and breaks by analyzing sensor data in near real-time to detect unusual flow rates and automatically notify dispatchers & field technicians about likely emergencies. For more information about this report visit http://www.researchandmarkets.com/research/9wdtmb/smart_gas_market


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "VoLTE Services & Subscribers Market Report - Regional 2016" report to their offering. The VoLTE Services & Subscribers Market Report provides accurate data and analyses - including market size, forecasts, and market trends - to help clients make better business decisions in the mobile VoIP services and subscribers market. - VoLTE Deployment Tracker lists deployments by service provider and start date for VoLTE and deployments by provider - Analyst-led conference call with presentation, plus one-on-one time with the analyst to ask questions I. Top Takeaways: VoLTE Is Ramping Up, but Revenue Remains to Be Seen II. VoLTE Is Quickly Ramping Up, with Improvements in Network Efficiencies as the Chief Driver a. In each of those 63 VoLTE networks, existing subscribers become de facto VoLTE users when they upgrade their device to an LTE-capable one b. The ramp up is good news but there is still no rush, even with the ecosystem in place, barriers removed and issues solved. . . c. . . . but in the meantime, the VoLTE front runners are ramping up VoLTE users! Asia Pacific is poised for driving the VoLTE market through 2020 For VoLTE related revenue, we looked at existing voice plans d. VoLTE roaming is the next big thing, fueling the LBO (RAVEL) vs. S8HR debate e. Meanwhile, the pace of commercialization of 3G mobile W-AMR HD voice continues to grow. . . f. . . . And native mVoIP has been available for some time g. Technical issues inherent to 3G are fixed but there is still no incentive to offer mVoIP as a service; good old voice is still good For more information about this report visit http://www.researchandmarkets.com/research/l8fw4m/volte_services


News Article | April 28, 2017
Site: www.prnewswire.com

The public 'Call to Action' launched in Berlin on April 28 urges G20 health ministers to commit new long-term investment in pandemic preparedness, and health technologies to combat antimicrobial resistance(AMR) and Poverty-Related and Neglected Diseases(PRNDs). "Meeting health targets outlined in the UN Sustainable Development Goals will require sustained investment and political will," coalition representatives said. "As representatives of the world's largest and wealthiest economies, the G20 must provide leadership. As we saw during the recent Ebola crisis in West Africa, the world is woefully unprepared to deal with pandemics. AMR, which includes drug resistant strains of HIV/AIDS, TB, malaria, diarrheal disease and pneumonia also poses an increasingly serious threat to public health." We urge the G20 to agree to provide the following: "These are diseases of poverty: 95% of cases are among poor and marginalised populations in low and middle-income countries. They also fuel the cycle of poverty, exacting a heavy economic toll on affected families and communities, which imposes a significant 'growth penalty' on entire regions. "Failure to invest now will lead to long-term costs. The World Bank has estimated that, without additional resources, these diseases will push an additional 28.3million people into poverty, increase global healthcare costs by $1.2trillion and cost low income countries more than 5% of GDP by 2050. "G20 leadership is vital if we are to successfully reduce the global disease burden, lift millions out of poverty and avert billions of dollars of economic and social costs." 1-The 'Call to Action' is launched today at G20 Global Health Innovation event in Berlin. 2-G20 health ministers meeting take places on May 19/20. For more information/interviews with Coalition:


News Article | April 28, 2017
Site: www.prnewswire.co.uk

The public 'Call to Action' launched in Berlin on April 28 urges G20 health ministers to commit new long-term investment in pandemic preparedness, and health technologies to combat antimicrobial resistance(AMR) and Poverty-Related and Neglected Diseases(PRNDs). "Meeting health targets outlined in the UN Sustainable Development Goals will require sustained investment and political will," coalition representatives said. "As representatives of the world's largest and wealthiest economies, the G20 must provide leadership. As we saw during the recent Ebola crisis in West Africa, the world is woefully unprepared to deal with pandemics. AMR, which includes drug resistant strains of HIV/AIDS, TB, malaria, diarrheal disease and pneumonia also poses an increasingly serious threat to public health." We urge the G20 to agree to provide the following: "These are diseases of poverty: 95% of cases are among poor and marginalised populations in low and middle-income countries. They also fuel the cycle of poverty, exacting a heavy economic toll on affected families and communities, which imposes a significant 'growth penalty' on entire regions. "Failure to invest now will lead to long-term costs. The World Bank has estimated that, without additional resources, these diseases will push an additional 28.3million people into poverty, increase global healthcare costs by $1.2trillion and cost low income countries more than 5% of GDP by 2050. "G20 leadership is vital if we are to successfully reduce the global disease burden, lift millions out of poverty and avert billions of dollars of economic and social costs." 1-The 'Call to Action' is launched today at G20 Global Health Innovation event in Berlin. 2-G20 health ministers meeting take places on May 19/20. For more information/interviews with Coalition:


News Article | April 20, 2017
Site: www.theguardian.com

The stark impact of antimicrobial resistance is all around us. Just a few weeks ago, a woman in the US who could not be treated with any available antibiotics (26 to be precise) died. And recently, results of a study demonstrated that four patients had malaria that was resistant to the most commonly used antimalarial in the UK. Similarly, we are seeing outbreaks of both gonorrhoea and fungal infections that are multi-resistant. The failure of treatment for gonorrhoea has been confirmed in at least 10 countries including the UK, Australia, Canada and France. Antimicrobial resistance is more common in some parts of the world than others. For example, it was estimated that there were 214,000 neonatal deaths attributable to resistant sepsis infections globally in 2013. 111,523 of these occurred in the five countries with the highest numbers of neonatal deaths in the world: India, Pakistan, Nigeria, Democratic Republic of Congo and China. A major area of concern for health professionals is drug-resistant tuberculosis. The World Health Organisation estimates that in 2014, there were about 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Soaring rates of multi-drug resistant tuberculosis have been found in west Africa, with the highest in the dense population of Lagos, Nigeria, suggesting the seriousness of the epidemic has been considerably underestimated. Although there is a lot of talk about antibiotic resistance in the future, it is important to realise that we are already seeing the impact of resistant infections in everyday life. Many urinary tract infections are becoming resistant, which can lead to people requiring a hospital stay. Sally Davies, chief medical officer for England, warned last year that 50,000 people are dying every year in Europe and the US from infections that antibiotics have lost the power to treat. Resistance is not a new problem. Alexander Fleming (1881–1955), who discovered penicillin, warned of the risk of resistance developing as far back as 1945. During his Nobel prize speech in 1945 he said: “The microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out which can be passed on to other individuals and perhaps from there to someone else and to others until they reach someone with a pneumonia which penicillin cannot save. I hope this evil can be averted.” Having fewer antibiotics that work will be equivalent to going back to the early 1930s, where infections we now consider trivial thanks to quick treatment by antibiotics will once again be fatal. An infected cut or illness such as pneumonia could once again become mass killers. Resistance is an expected consequence of antibiotic use and its spread is a result of poor infection prevention and control. A recent global review on antimicrobial resistance (AMR) highlighted that if we do not act now to tackle AMR, infections that are resistant to antimicrobials will kill 10 million people by 2050, and that between 2016 and 2050 the world could expect to lose between $60tn and $100tn worth of economic output [pdf]. The impact of such a cost has been likened by the World Bank to that caused by the 2008 financial crisis. Our Antibiotic Guardian campaign allows everyone to sign up to a pledge, health professionals or members of the public. Midwives can pledge to make sure mothers are only given drugs they need and know how to use them. Dentists can pledge to consider drainage for dental issues before using antibiotics. Farmers can pledge to annually review and discuss the antibiotic use on their farm with a vet, and look for ways of optimising use as necessary. We want people to learn what actions they can personally take to help tackle the problem. Evaluation of the initiative shows that the campaign changes behaviour and increases knowledge and also increases commitment to tackling AMR. We are also aiming to educate children about the importance of antibiotics. The E-Bug school programme provides resources and educational games in 22 languages covering infection protection and control as well as explaining antibiotics. In addition to ensuring we make appropriate use of antibiotics for human health, AMR has clear links to both animal health, farming and the environment. The importance of tackling AMR using what we call a “one health” approach is now widely recognised. The approach is defined as “... the collaborative effort of multiple disciplines to attain optimal health for people, animals and our environment …”. In the UK, for example, the strategy to tackle antimicrobial resistance takes a one health approach with actions for human, animal and environmental health. No new class of antibiotics has been discovered for a number of years. Even if we discover more, simply replacing old antibiotics with new ones is not the only answer as they could also become ineffective. It is therefore important that everyone does their part to tackle this issue. Diane Ashiru-Oredope is pharmacist lead for antimicrobial resistance and stewardship at Public Health England. Join our community of development professionals and humanitarians. Follow @GuardianGDP on Twitter.


News Article | April 24, 2017
Site: www.marketwired.com

TORONTO, ONTARIO--(Marketwired - April 24, 2017) - Asian Mineral Resources Limited ("AMR" or the "Company") (TSX VENTURE:ASN) is pleased to announce that it has entered into a net smelter royalty return agreement (the "NSR Agreement") with Cobalt 27 Capital Corp. ("Cobalt 27") related to the sale of cobalt by AMR from its Ta Khoa concession in Vietnam. Under the terms of the NSR Agreement, AMR will receive C$300,000 equivalent in common shares of Cobalt 27 in exchange for granting Cobalt 27 a 3% net smelter return on sales of cobalt from the Ta Khoa concession. The price per common share will be equal to the price per common share offered by Cobalt 27 pursuant to its offering of common shares (the "Cobalt 27 Offering") under its preliminary prospectus dated April 21, 2017. Receipt of the common shares from Cobalt 27 as payment and the effectiveness of the NSR Agreement is dependent on certain matters being completed, including the receipt of material third party consents and the closing of the Cobalt 27 Offering, on or before September 30, 2017. AMR owns and operates one of the world's few sources of nickel sulphide ore, and is exploring for additional high-grade nickel assets in Vietnam. AMR commenced commercial production from its 90%- owned Ban Phuc Nickel Mine in Vietnam in mid-2013. As of 30 June 2016, the Ban Phuc Nickel Mine has produced a total of c. 20,000 tonnes of nickel and c. 10,000 tonnes of copper contained in concentrate, plus a cobalt by-product since the beginning of its mine life. Mining and processing operations at Ban Phuc were suspended in September 2016 and operations were transitioned to a care and maintenance scenario. In addition to in and near-mine expansion projects, Ban Phuc provides a platform from which AMR can continue to focus on developing a new nickel camp within its 150km2 of concessions located throughout the highly-prolific Song Da rift zone, where AMR has a number of advanced-stage nickel exploration targets. For further details on AMR, please refer to the technical report entitled "NI 43-101 Technical Report - Ban Phuc Nickel Project" dated February 15, 2013 available on SEDAR or the AMR website www.asianmineralres.com. This press release includes certain "Forward-Looking Statements." All statements, other than statements of historical fact, included herein, including without limitation, the completion of conditions precedent under the NSR Agreement, completion of the Cobalt 27 financing and receipt of payment under the NSR Agreement, potential mineralization and reserve and resource estimates, exploration results and future plans and objectives of AMR are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of AMR to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from AMR's expectations are disclosed under the heading "Risk Factors" in AMR's Annual Information Form, and elsewhere in AMR's documents filed from time-to-time with the TSX Venture Exchange and other regulatory authorities. Such forward-looking statements are based on a number of material factors and assumptions, including: that contracted parties provide goods and/or services on the agreed timeframes; that parties are able to complete financings on agreeable terms; that third parties provide required consents acting reasonably; that on-going contractual negotiations will be successful and progress and/or be completed in a timely manner; that application for permits and licences will be granted/obtained in a timely manner; that no unusual geological or technical problems occur; that plant and equipment work as anticipated and that there is no material adverse change in the price of applicable minerals and metals. Although AMR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this press release. AMR disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries. Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance. To that end, ATLAS can not only help physicians select the most appropriate treatment choices for their patients, but also enable global health authorities to develop data-driven antimicrobial resistance mitigation strategies. Pfizer will formally unveil ATLAS on April 22nd at the annual meeting of the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna. Mobile devices and applications provide many benefits for healthcare professionals including increased access to point of care tools, which have been shown to support better clinical decision making and improved patient outcomes. In response to this need, Pfizer also offers ATLAS as a mobile application to enable rapid access to important resistance information at the point of patient care. ATLAS offers an interactive platform that enables physicians to evaluate data, conduct analyses, and export tables and figures that include parameters such as pathogen, region, specimen source and in vitro susceptibility data. The ATLAS database is updated every six months with new resistance data from healthcare institutions in more than 60 countries as these become available. ATLAS can be accessed by visiting: www.atlas-surveillance.com. “An important aspect for physicians when treating patients is knowledge; knowledge of where certain resistant bacterial infections tend to occur and knowledge of which antibiotics remain effective against them,” said Dr. Freda Lewis-Hall, Chief Medical Officer of Pfizer Inc. “ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilization of antibiotics and improve infection prevention and control.” The World Health Organization (WHO) characterizes antimicrobial resistance as one of the biggest threats to global health, that can affect anyone at any age in any country, threatening our ability to treat serious infections and provide standard medical procedures. Gram-negative bacteria, the cause of many healthcare-associated infections (HAIs), have become increasingly resistant to many available antibiotic treatments. These infections are associated with increased patient mortality and cost of care. At present, approximately 700,000 deaths per year are attributed to antimicrobial resistance globally, with an increase to 10 million predicted by 2050 if no action is taken to address this issue. Today, Pfizer is the leading global provider of anti-infective medicines in the industry, offering patients access to a diverse portfolio of more than 80 products. Pfizer recognizes the serious public health threat associated with AMR and has taken significant steps to address this issue. In early 2016, Pfizer was a signatory of the Declaration on Combating Antimicrobial Resistance (AMR), a global call-to-action drafted and signed by more than 100 companies and 13 trade associations encouraging greater industry and government collaboration to address the issue of antimicrobial resistance. As a follow-up to the AMR Declaration, Pfizer and 13 industry partners unveiled the “Industry Roadmap to Combat Antimicrobial Resistance,” a comprehensive plan of action, that lays out four key commitments we pledge to deliver by 2020. For more information on Pfizer’s commitment to AMR, please click here. Since its pioneering work on penicillin in the 1940s, Pfizer has been actively engaged in the research and development of innovative medicines, policies and educational programs to address the evolving needs of patients and physicians in the area of infectious diseases. For more than 30 years, Pfizer has been a leader in developing and implementing innovative public-private partnerships designed to address unmet medical needs and global public health issues. Today, our patient assistance programs expand access to potentially lifesaving medicines and provide educational resources that empower patients and physicians in the fight against infectious disease. Pfizer Inc.: Working together for a healthier world® At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Loading AMR collaborators
Loading AMR collaborators